

Gastroenterology Enrollment Form



25329 Budde Road, Suite #104
Spring, TX 77380
Phone: 832-713-6119 . Fax: 281-809-6917

PATIENT INFORMATION

Name: _____ DOB: _____ Gender: ☐ M ☐ F
Address: _____ City: _____ State: _____ Zip: _____
Phone: _____ Alt. Phone: _____ Email: _____
Language : ☐ English ☐ Spanish ☐ Other: _____ Height: _____ Weight: _____

STATEMENT OF MEDICAL NECESSITY

DIAGNOSIS (ICD-10 CODES): ☐ **K50.90** Crohn's Disease ☐ **K51.80** Ulcerative Colitis ☐ **K58.0** Irritable Bowel Syndrome With Diarrhea (IBS-D)
Other: _____ Date: _____ Allergies: _____ ☐ **NKDA**

Prior Failed Treatments:

Biologics: ☐ Humira ☐ Enbrel ☐ Remicade ☐ Other: _____
☐ 5-ASA ☐ Azathioprine ☐ Corticosteroids
☐ Methotrexate ☐ 6-MP ☐ Sulfasalazine ☐ Other: _____

Patient Evaluation:

☐ Crohn's Severity: ☐ Moderate ☐ Severe
☐ TB Test ☐ Positive ☐ Negative
☐ Hep B ruled out or treatment started? ☐ Yes ☐ No

PRESCRIPTION INFORMATION

| Medication | Dose & Strength | Directions | Qty | Refills |
|--|--|---|-------|---------|
| <input type="checkbox"/> AVSOLA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ENTYVIO® | <input type="checkbox"/> 300mg Vial | <input type="checkbox"/> Infused 300mg IV over 30min at week 0, week 2, week 6 then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> HUMIRA® | <input type="checkbox"/> Crohn's Starter Pack <input type="checkbox"/> 40mg Injectible Pen <input type="checkbox"/> 40mg Prefilled Syringe | <input type="checkbox"/> Induction Dose: Inject Subq 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> HUMIRA CF® (Citrate-free) | <input type="checkbox"/> Humira Starter Pack CD/UC/HS <input type="checkbox"/> 40mg Pen <input type="checkbox"/> 40mg Prefilled Syringe | Weight (>88lbs) <input type="checkbox"/> Induction Dose: Inject subcutaneously 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> INFLECTRA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> INJECTAFER® | <input type="checkbox"/> 15mg/kg <input type="checkbox"/> 750mg | <input type="checkbox"/> 15mg/kg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing less than 50kg (110lbs) <input type="checkbox"/> 750mg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing 50kg (110lbs) or greater <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> REMICADE® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> RENFLXIS® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> SIMPONI ARIA® | <input type="checkbox"/> 50mg/4ml | <input type="checkbox"/> Induction Dose: Infused 2mg/kg at week 0, 4 then every 8 weeks. <input type="checkbox"/> Maintenance Dose: Infused 2mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> STELARA® | <input type="checkbox"/> 130mg/26ml Vial <input type="checkbox"/> 90mg/ml Syringe | <input type="checkbox"/> Induction Dose: Infuse _____ mg x dose. (<input type="checkbox"/> 55kg or less—260mg; <input type="checkbox"/> 55-85kg—390mg; <input type="checkbox"/> 85kg or more—520mg) <input type="checkbox"/> Maintenance Dose: 90mg Subq 8 weeks after initial and then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ZINPLAVA® | <input type="checkbox"/> 25mg/ml | <input type="checkbox"/> The recommended dose is a single dose of 10 mg/kg administered as an intravenous infusion over 60 minutes. <input type="checkbox"/> Others: | | |

Prescriber's Signature: _____ ☐ **DAW (Dispense As Written)** Date: _____

Prescriber's Name: _____ Phone: _____ Fax: _____

Prescriber's Address: _____ City: _____ State: _____ Zip: _____

NPI: _____ DEA: _____ Tax I.D: _____ Office Contact: _____

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

Gastroenterology Enrollment Form



25329 Budde Road, Suite #104
Spring, TX 77380
Phone: 832-713-6119 . Fax: 281-809-6917

PATIENT INFORMATION

Name: _____ DOB: _____ Gender: ☐ M ☐ F
Address: _____ City: _____ State: _____ Zip: _____
Phone: _____ Alt. Phone: _____ Email: _____
Language : ☐ English ☐ Spanish ☐ Other: _____ Height: _____ Weight: _____

STATEMENT OF MEDICAL NECESSITY

DIAGNOSIS (ICD-10 CODES): ☐ **K50.90** Crohn's Disease ☐ **K51.80** Ulcerative Colitis ☐ **K58.0** Irritable Bowel Syndrome With Diarrhea (IBS-D)
Other: _____ Date: _____ Allergies: _____ ☐ **NKDA**

Prior Failed Treatments:

Biologics: ☐ Humira ☐ Enbrel ☐ Remicade ☐ Other: _____
☐ 5-ASA ☐ Azathioprine ☐ Corticosteroids
☐ Methotrexate ☐ 6-MP ☐ Sulfasalazine ☐ Other: _____

Patient Evaluation:

☐ Crohn's Severity: ☐ Moderate ☐ Severe
☐ TB Test ☐ Positive ☐ Negative
☐ Hep B ruled out or treatment started? ☐ Yes ☐ No

PRESCRIPTION INFORMATION

| Medication | Dose & Strength | Directions | Qty | Refills |
|--|--|---|-------|---------|
| <input type="checkbox"/> AVSOLA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ENTYVIO® | <input type="checkbox"/> 300mg Vial | <input type="checkbox"/> Infused 300mg IV over 30min at week 0, week 2, week 6 then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> HUMIRA® | <input type="checkbox"/> Crohn's Starter Pack <input type="checkbox"/> 40mg Injectible Pen <input type="checkbox"/> 40mg Prefilled Syringe | <input type="checkbox"/> Induction Dose: Inject Subq 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> HUMIRA CF® (Citrate-free) | <input type="checkbox"/> Humira Starter Pack CD/UC/HS <input type="checkbox"/> 40mg Pen <input type="checkbox"/> 40mg Prefilled Syringe | Weight (>88lbs) <input type="checkbox"/> Induction Dose: Inject subcutaneously 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> INFLECTRA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> INJECTAFER® | <input type="checkbox"/> 15mg/kg <input type="checkbox"/> 750mg | <input type="checkbox"/> 15mg/kg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing less than 50kg (110lbs) <input type="checkbox"/> 750mg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing 50kg (110lbs) or greater <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> REMICADE® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> RENFLXIS® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> SIMPONI ARIA® | <input type="checkbox"/> 50mg/4ml | <input type="checkbox"/> Induction Dose: Infused 2mg/kg at week 0, 4 then every 8 weeks. <input type="checkbox"/> Maintenance Dose: Infused 2mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> STELARA® | <input type="checkbox"/> 130mg/26ml Vial <input type="checkbox"/> 90mg/ml Syringe | <input type="checkbox"/> Induction Dose: Infuse _____ mg x dose. (<input type="checkbox"/> 55kg or less—260mg; <input type="checkbox"/> 55-85kg—390mg; <input type="checkbox"/> 85kg or more—520mg) <input type="checkbox"/> Maintenance Dose: 90mg Subq 8 weeks after initial and then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ZINPLAVA® | <input type="checkbox"/> 25mg/ml | <input type="checkbox"/> The recommended dose is a single dose of 10 mg/kg administered as an intravenous infusion over 60 minutes . <input type="checkbox"/> Others: | | |

Prescriber's Signature: _____ ☐ **DAW (Dispense As Written)** Date: _____

Prescriber's Name: _____ Phone: _____ Fax: _____

Prescriber's Address: _____ City: _____ State: _____ Zip: _____

NPI: _____ DEA: _____ Tax I.D: _____ Office Contact: _____

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

Gastroenterology Enrollment Form



25329 Budde Road, Suite #104
Spring, TX 77380
Phone: 832-713-6119 . Fax: 281-809-6917

PATIENT INFORMATION

Name: _____ DOB: _____ Gender: ☐ M ☐ F
Address: _____ City: _____ State: _____ Zip: _____
Phone: _____ Alt. Phone: _____ Email: _____
Language : ☐ English ☐ Spanish ☐ Other: _____ Height: _____ Weight: _____

STATEMENT OF MEDICAL NECESSITY

DIAGNOSIS (ICD-10 CODES): ☐ **K50.90** Crohn's Disease ☐ **K51.80** Ulcerative Colitis ☐ **K58.0** Irritable Bowel Syndrome With Diarrhea (IBS-D)
Other: _____ Date: _____ Allergies: _____ ☐ **NKDA**

Prior Failed Treatments:

Biologics: ☐ Humira ☐ Enbrel ☐ Remicade ☐ Other: _____
☐ 5-ASA ☐ Azathioprine ☐ Corticosteroids
☐ Methotrexate ☐ 6-MP ☐ Sulfasalazine ☐ Other: _____

Patient Evaluation:

☐ Crohn's Severity: ☐ Moderate ☐ Severe
☐ TB Test ☐ Positive ☐ Negative
☐ Hep B ruled out or treatment started? ☐ Yes ☐ No

PRESCRIPTION INFORMATION

| Medication | Dose & Strength | Directions | Qty | Refills |
|--|--|---|-------|---------|
| <input type="checkbox"/> AVSOLA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ENTYVIO® | <input type="checkbox"/> 300mg Vial | <input type="checkbox"/> Infused 300mg IV over 30min at week 0, week 2, week 6 then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> HUMIRA® | <input type="checkbox"/> Crohn's Starter Pack <input type="checkbox"/> 40mg Injectible Pen <input type="checkbox"/> 40mg Prefilled Syringe | <input type="checkbox"/> Induction Dose: Inject Subq 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> HUMIRA CF® (Citrate-free) | <input type="checkbox"/> Humira Starter Pack CD/UC/HS <input type="checkbox"/> 40mg Pen <input type="checkbox"/> 40mg Prefilled Syringe | Weight (>88lbs) <input type="checkbox"/> Induction Dose: Inject subcutaneously 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> INFLECTRA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> INJECTAFER® | <input type="checkbox"/> 15mg/kg <input type="checkbox"/> 750mg | <input type="checkbox"/> 15mg/kg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing less than 50kg (110lbs) <input type="checkbox"/> 750mg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing 50kg (110lbs) or greater <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> REMICADE® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> RENFLXIS® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> SIMPONI ARIA® | <input type="checkbox"/> 50mg/4ml | <input type="checkbox"/> Induction Dose: Infused 2mg/kg at week 0, 4 then every 8 weeks. <input type="checkbox"/> Maintenance Dose: Infused 2mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> STELARA® | <input type="checkbox"/> 130mg/26ml Vial <input type="checkbox"/> 90mg/ml Syringe | <input type="checkbox"/> Induction Dose: Infuse _____ mg x dose. (<input type="checkbox"/> 55kg or less—260mg; <input type="checkbox"/> 55-85kg—390mg; <input type="checkbox"/> 85kg or more—520mg) <input type="checkbox"/> Maintenance Dose: 90mg Subq 8 weeks after initial and then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ZINPLAVA® | <input type="checkbox"/> 25mg/ml | <input type="checkbox"/> The recommended dose is a single dose of 10 mg/kg administered as an intravenous infusion over 60 minutes. <input type="checkbox"/> Others: | | |

Prescriber's Signature: _____ ☐ **DAW (Dispense As Written)** Date: _____

Prescriber's Name: _____ Phone: _____ Fax: _____

Prescriber's Address: _____ City: _____ State: _____ Zip: _____

NPI: _____ DEA: _____ Tax I.D: _____ Office Contact: _____

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

Gastroenterology Enrollment Form



25329 Budde Road, Suite #104
Spring, TX 77380
Phone: 832-713-6119 . Fax: 281-809-6917

PATIENT INFORMATION

Name: _____ DOB: _____ Gender: ☐ M ☐ F
Address: _____ City: _____ State: _____ Zip: _____
Phone: _____ Alt. Phone: _____ Email: _____
Language : ☐ English ☐ Spanish ☐ Other: _____ Height: _____ Weight: _____

STATEMENT OF MEDICAL NECESSITY

DIAGNOSIS (ICD-10 CODES): ☐ **K50.90** Crohn's Disease ☐ **K51.80** Ulcerative Colitis ☐ **K58.0** Irritable Bowel Syndrome With Diarrhea (IBS-D)
Other: _____ Date: _____ Allergies: _____ ☐ **NKDA**

Prior Failed Treatments:

Biologics: ☐ Humira ☐ Enbrel ☐ Remicade ☐ Other: _____
☐ 5-ASA ☐ Azathioprine ☐ Corticosteroids
☐ Methotrexate ☐ 6-MP ☐ Sulfasalazine ☐ Other: _____

Patient Evaluation:

☐ Crohn's Severity: ☐ Moderate ☐ Severe
☐ TB Test ☐ Positive ☐ Negative
☐ Hep B ruled out or treatment started? ☐ Yes ☐ No

PRESCRIPTION INFORMATION

| Medication | Dose & Strength | Directions | Qty | Refills |
|--|--|---|-------|---------|
| <input type="checkbox"/> AVSOLA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ENTYVIO® | <input type="checkbox"/> 300mg Vial | <input type="checkbox"/> Infused 300mg IV over 30min at week 0, week 2, week 6 then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> HUMIRA® | <input type="checkbox"/> Crohn's Starter Pack <input type="checkbox"/> 40mg Injectible Pen <input type="checkbox"/> 40mg Prefilled Syringe | <input type="checkbox"/> Induction Dose: Inject Subq 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> HUMIRA CF® (Citrate-free) | <input type="checkbox"/> Humira Starter Pack CD/UC/HS <input type="checkbox"/> 40mg Pen <input type="checkbox"/> 40mg Prefilled Syringe | Weight (>88lbs) <input type="checkbox"/> Induction Dose: Inject subcutaneously 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> INFLECTRA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> INJECTAFER® | <input type="checkbox"/> 15mg/kg <input type="checkbox"/> 750mg | <input type="checkbox"/> 15mg/kg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing less than 50kg (110lbs) <input type="checkbox"/> 750mg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing 50kg (110lbs) or greater <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> REMICADE® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> RENFLXIS® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> SIMPONI ARIA® | <input type="checkbox"/> 50mg/4ml | <input type="checkbox"/> Induction Dose: Infused 2mg/kg at week 0, 4 then every 8 weeks. <input type="checkbox"/> Maintenance Dose: Infused 2mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> STELARA® | <input type="checkbox"/> 130mg/26ml Vial <input type="checkbox"/> 90mg/ml Syringe | <input type="checkbox"/> Induction Dose: Infuse _____ mg x dose. (<input type="checkbox"/> 55kg or less—260mg; <input type="checkbox"/> 55-85kg—390mg; <input type="checkbox"/> 85kg or more—520mg) <input type="checkbox"/> Maintenance Dose: 90mg Subq 8 weeks after initial and then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ZINPLAVA® | <input type="checkbox"/> 25mg/ml | <input type="checkbox"/> The recommended dose is a single dose of 10 mg/kg administered as an intravenous infusion over 60 minutes . <input type="checkbox"/> Others: | | |

Prescriber's Signature: _____ ☐ **DAW (Dispense As Written)** Date: _____


Prescriber's Name: _____ Phone: _____ Fax: _____

Prescriber's Address: _____ City: _____ State: _____ Zip: _____

NPI: _____ DEA: _____ Tax I.D: _____ Office Contact: _____

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.

Gastroenterology Enrollment Form



25329 Budde Road, Suite #104
Spring, TX 77380
Phone: 832-713-6119 . Fax: 281-809-6917

PATIENT INFORMATION

Name: _____ DOB: _____ Gender: ☐ M ☐ F
Address: _____ City: _____ State: _____ Zip: _____
Phone: _____ Alt. Phone: _____ Email: _____
Language : ☐ English ☐ Spanish ☐ Other: _____ Height: _____ Weight: _____

STATEMENT OF MEDICAL NECESSITY

DIAGNOSIS (ICD-10 CODES): ☐ **K50.90** Crohn's Disease ☐ **K51.80** Ulcerative Colitis ☐ **K58.0** Irritable Bowel Syndrome With Diarrhea (IBS-D)
Other: _____ Date: _____ Allergies: _____ ☐ **NKDA**

Prior Failed Treatments:

Biologics: ☐ Humira ☐ Enbrel ☐ Remicade ☐ Other: _____
☐ 5-ASA ☐ Azathioprine ☐ Corticosteroids
☐ Methotrexate ☐ 6-MP ☐ Sulfasalazine ☐ Other: _____

Patient Evaluation:

☐ Crohn's Severity: ☐ Moderate ☐ Severe
☐ TB Test ☐ Positive ☐ Negative
☐ Hep B ruled out or treatment started? ☐ Yes ☐ No

PRESCRIPTION INFORMATION

| Medication | Dose & Strength | Directions | Qty | Refills |
|--|--|---|-------|---------|
| <input type="checkbox"/> AVSOLA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ENTYVIO® | <input type="checkbox"/> 300mg Vial | <input type="checkbox"/> Infused 300mg IV over 30min at week 0, week 2, week 6 then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> HUMIRA® | <input type="checkbox"/> Crohn's Starter Pack <input type="checkbox"/> 40mg Injectible Pen <input type="checkbox"/> 40mg Prefilled Syringe | <input type="checkbox"/> Induction Dose: Inject Subq 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> HUMIRA CF® (Citrate-free) | <input type="checkbox"/> Humira Starter Pack CD/UC/HS <input type="checkbox"/> 40mg Pen <input type="checkbox"/> 40mg Prefilled Syringe | Weight (>88lbs) <input type="checkbox"/> Induction Dose: Inject subcutaneously 160mg on day 1, then 80mg on day 15, then maintenance. <input type="checkbox"/> Maintenance Dose: Inject subcutaneously 40mg every other week. | | |
| <input type="checkbox"/> INFLECTRA® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> INJECTAFER® | <input type="checkbox"/> 15mg/kg <input type="checkbox"/> 750mg | <input type="checkbox"/> 15mg/kg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing less than 50kg (110lbs) <input type="checkbox"/> 750mg IV - Give 2 doses at least 7 days apart not to exceed 1500mg. if patient weighing 50kg (110lbs) or greater <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> REMICADE® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> RENFLXIS® | <input type="checkbox"/> 100mg Vial | <input type="checkbox"/> Induction Dose: IV at 5 mg/kg at week 0, week 2, week 6 and every 8 weeks thereafter. <input type="checkbox"/> Maintenance Dose: IV at 5 mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> SIMPONI ARIA® | <input type="checkbox"/> 50mg/4ml | <input type="checkbox"/> Induction Dose: Infused 2mg/kg at week 0, 4 then every 8 weeks. <input type="checkbox"/> Maintenance Dose: Infused 2mg/kg every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> STELARA® | <input type="checkbox"/> 130mg/26ml Vial <input type="checkbox"/> 90mg/ml Syringe | <input type="checkbox"/> Induction Dose: Infuse _____ mg x dose. (<input type="checkbox"/> 55kg or less—260mg; <input type="checkbox"/> 55-85kg—390mg; <input type="checkbox"/> 85kg or more—520mg) <input type="checkbox"/> Maintenance Dose: 90mg Subq 8 weeks after initial and then every 8 weeks. <input type="checkbox"/> Others: | | |
| <input type="checkbox"/> ZINPLAVA® | <input type="checkbox"/> 25mg/ml | <input type="checkbox"/> The recommended dose is a single dose of 10 mg/kg administered as an intravenous infusion over 60 minutes . <input type="checkbox"/> Others: | | |

Prescriber's Signature: _____ ☐ **DAW (Dispense As Written)** Date: _____

Prescriber's Name: _____ Phone: _____ Fax: _____

Prescriber's Address: _____ City: _____ State: _____ Zip: _____

NPI: _____ DEA: _____ Tax I.D: _____ Office Contact: _____

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.